Expression and activities of aldo-keto oxidoreductases in Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 60, Issue 7, 2001, Pages 686-695

  Picklo Sr , Matthew J ^a,d   Olson, Sandra J ^a   Markesbery, William R ^c   Montine, Thomas J ^a,b  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NORTH DAKOTA   (United States)

Author keywords

4 Hydroxynonenal; Aldehyde dehydrogenase; Aldose reductase; Alzheimer disease

Indexed keywords

4 HYDROXYNONENAL; ALCOHOL DEHYDROGENASE; ALDEHYDE; ALDEHYDE DEHYDROGENASE; ALDEHYDE REDUCTASE;

ALZHEIMER DISEASE; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME LOCALIZATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; ISOELECTRIC FOCUSING; LIPID PEROXIDATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0034944147     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnen/60.7.686     Document Type: Article

References (61)

1. Chemistry and biochemistry of 4-hydroxynonenal, malondialdehyde, and related aldehydes
2. Biological interactions of α,β-unsaturated aldehydes
3. Covalent modifications of aminophospholipids by 4-hydroxynonenal
4. Reactions of 4-hydroxy-2(E)-nonenal and related aldehydes with proteins studied by carbon-13 nuclear magnetic resonance spectroscopy
5. Pyrrole formation from 4-hydroxynonenal and primary amines
6. 4-Hydroxy-2-nonenal pyrrole adducts in human neurodegenerative disease
7. Immunohistochemical detection of 4-hydroxy-2-nonenal adducts in Alzheimer's disease is associated with inheritance of APOE4
8. Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype
9. Protein-bound acrolein: A novel marker of oxidative stress in Alzheimer's disease
10. Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease
11. (E)-4-hydroxynonenal may be involved in the pathogenesis of Parkinson's disease
12. Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis
13. 4-Hydroxynonenal-derived advanced lipid peroxidation end products are increased in Alzheimer's disease
14. 4-Hydroxy-2(E)-nonenal inhibits CNS mitochondrial respiration at multiple sites
15. The lipid peroxidation product 4-hydroxynonenal inhibits neurite outgrowth, disrupts neuronal microtubules, and modifies cellular tubulin
16. 4-Hydroxynonenal inhibits Na+-K+ATPase
17. 4-Hydroxynonenal, an aldehydic product of membrane lipid peroxidation, impairs glutamate transport and mitochondrial function in synaptosomes
18. 4-Hydroxynonenal increase neuronal susceptibility to oxidative stress
19. Evidence that 4-hydroxynonenal mediates oxidative stress-induced neuronal apoptosis
20. A role for 4-hydroxynonenal, an aldehydic product of lipid peroxidation, in disruption of ion homeostasis and neuronal death induced by amyloid beta-peptide
21. Amyloid beta-peptide impairs glucose transport in hippocampal and cortical neurons: Involvement of membrane lipid peroxidation
22. Human glutathione transferase A4-4: An alpha class enzyme with high catalytic efficiency in the conjugation of 4-hydroxynonenal and other genotoxic products of lipid peroxidation
23. Glutathione transferase protects neuronal cultures against four hydroxynonenal toxicity
24. Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer's disease
25. The oxidation of α,β, unsaturated aldehydic products in lipid peroxidation by rat liver aldehyde dehydrogenases
26. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members
27. Human brain glyceraldehyde-3-phosphate dehydrogenase, succinic semialdehyde dehydrogenase and aldehyde dehydrogenase isozymes: Substrate specificity and sensitivity to disulfiram
28. Lipid aldehyde oxidation as a physiological role for class 3 aldehdye dehyrdogenases
29. Purification and characterization of aldehyde dehydrogenase from human brain
30. Distribution of messenger RNAs for aldehyde dehydrogenase1, aldehyde dehydrogenase 2, and aldehyde dehydrogenase 5 in human tissues
31. Partial purification and properties of human brain aldehdye dehydrogenases
32. Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population
33. Oxidation and reduction of 4-hydroxyalkenals catalyzed by isozymes of human alcohol dehydrogenase
34. Metabolism of the lipid peroxidation product, 4-hydroxy-trans-2-nonenal, in isolated perfused rat heart
35. Structural and kinetic determinants of aldehyde reduction by aldose reductase
36. Histological distribution of class III alcohol dehydrogenase in human brain
37. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II. Standardization of the neuropatholic assessment of Alzheimer's disease
38. Microtiter plate-based determination of multiple concentration-inhibition relationships
39. Distribution and properties of aldehdye dehydrogenase in regions of rat brain
40. Microdetermination of aldose and aldehyde reductase from human tissue
41. Stabilizating the alkali-generated fluorescent derivatives of NAD and NADP
42. Inhibition of hexonate dehydrogenase and aldose reductase from bovine retina by sorbinil, statil, M79175 and valproate
43. A highly specific aldose reductase inhibitor, ethyl 1-benzyl-3 hydroxy-2(5H)-oxopyrrole-4-carboxylate, and its congeners
44. 4-Hydroxy-2,3-trans-nonenal induces transcription and expression of aldose reductase
45. Purification and characterization of human-brain aldose reductase
46. Macrophages/microglial cells in human central nervous system during development: An immunohistochemical study
47. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease
48. Oxidative stress hypothesis in Alzheimer's disease
49. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease
50. Glutathione and glutathione-dependent enzymes represent a coordinately regulated defence against oxidative stress
51. Decreased thioredoxin and increased thioredoxin reductase levels in Alzheimer's disease brain
52. Decreased base excision repair and increased helicase activity in Alzheimer's disease brain
53. Localization of superoxide dismutases in Alzheimer's disease and Down's syndrome neocortex and hippocampus
54. Expression of heme oxygenase-I in the senescent and Alzheimer-diseased brain
55. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease
56. Cytochemical demonstration of oxidative damage in Alzheimer disease by immunochemical enhancement of the carbonyl reaction with 2,4-dinitrophenylhydrazine
57. Formation of novel D-ring and E-ring isoprostane-like compounds (D4/E4-neuroprostanes) in vivo from docosahexaenoic acid
58. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease
59. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer's disease
60. S-methylation as a bioactivation mechanism for mono- and dithiocarbamate pesticides as aldehyde dehydrogenase inhibitors